Is Theravance Biopharma Stock a Good Investment?
Theravance Biopharma Investment Advice | TBPH |
- Examine Theravance Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Theravance Biopharma's leadership team and their track record. Good management can help Theravance Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Theravance Biopharma's business and its evolving consumer preferences.
- Compare Theravance Biopharma's performance and market position to its competitors. Analyze how Theravance Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Theravance Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Theravance Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Theravance Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Theravance Biopharma is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Theravance Biopharma Stock
Researching Theravance Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The book value of Theravance Biopharma was at this time reported as 3.79. The company recorded a loss per share of 1.03. Theravance Biopharma had not issued any dividends in recent years.
To determine if Theravance Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theravance Biopharma's research are outlined below:
| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Theravance Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Theravance Biopharma to Present at Evercore HealthCONx Conference TBPH Stock News - StockTitan |
Theravance Biopharma Quarterly Cash And Short Term Investments |
|
Theravance Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theravance Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theravance Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Theravance Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Theravance Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-26 | 2023-12-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2023-02-27 | 2022-12-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2022-11-07 | 2022-09-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2023-11-07 | 2023-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2024-08-05 | 2024-06-30 | -0.21 | -0.28 | -0.07 | 33 | ||
2023-08-07 | 2023-06-30 | -0.21 | -0.28 | -0.07 | 33 | ||
2021-11-03 | 2021-09-30 | -0.56 | -0.48 | 0.08 | 14 | ||
2023-05-08 | 2023-03-31 | -0.26 | -0.35 | -0.09 | 34 |
Know Theravance Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Theravance Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Theravance Biopharma backward and forwards among themselves. Theravance Biopharma's institutional investor refers to the entity that pools money to purchase Theravance Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2024-06-30 | 878.7 K | Geode Capital Management, Llc | 2024-06-30 | 857.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 758.1 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 586.6 K | Bank Of America Corp | 2024-06-30 | 476.2 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 458.4 K | Northern Trust Corp | 2024-09-30 | 383.8 K | Wellington Management Company Llp | 2024-06-30 | 350.6 K | Nuveen Asset Management, Llc | 2024-06-30 | 342.7 K | Madison Avenue Partners, Lp | 2024-06-30 | 8.5 M | Weiss Asset Management Lp | 2024-06-30 | 7.5 M |
Theravance Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 490.27 M.Market Cap |
|
Theravance Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.15) | (0.14) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.26) | (0.25) |
Determining Theravance Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Theravance Biopharma is a good buy. For example, gross profit margin measures Theravance Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theravance Biopharma's profitability and make more informed investment decisions.
Evaluate Theravance Biopharma's management efficiency
Theravance Biopharma has return on total asset (ROA) of (0.0641) % which means that it has lost $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2288) %, meaning that it created substantial loss on money invested by shareholders. Theravance Biopharma's management efficiency ratios could be used to measure how well Theravance Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The Theravance Biopharma's current Return On Capital Employed is estimated to increase to -0.14. As of now, Theravance Biopharma's Non Current Assets Total are increasing as compared to previous years. The Theravance Biopharma's current Non Currrent Assets Other is estimated to increase to about 213.3 M, while Other Current Assets are projected to decrease to under 11.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.85 | 4.04 | |
| Tangible Book Value Per Share | 3.85 | 4.04 | |
| Enterprise Value Over EBITDA | (15.45) | (16.22) | |
| Price Book Value Ratio | 2.92 | 3.06 | |
| Enterprise Value Multiple | (15.45) | (16.22) | |
| Price Fair Value | 2.92 | 3.06 | |
| Enterprise Value | 838.1 M | 801.7 M |
Effective leadership at Theravance Biopharma drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.251 |
Basic technical analysis of Theravance Stock
As of the 21st of November, Theravance Biopharma has the Semi Deviation of 1.27, risk adjusted performance of 0.1231, and Coefficient Of Variation of 644.96. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theravance Biopharma, as well as the relationship between them.Theravance Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theravance Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theravance Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theravance Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Theravance Biopharma's Outstanding Corporate Bonds
Theravance Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Theravance Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Theravance bonds can be classified according to their maturity, which is the date when Theravance Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Theravance Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Theravance Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1231 | |||
| Market Risk Adjusted Performance | 0.2756 | |||
| Mean Deviation | 1.44 | |||
| Semi Deviation | 1.27 | |||
| Downside Deviation | 1.54 | |||
| Coefficient Of Variation | 644.96 | |||
| Standard Deviation | 2.02 | |||
| Variance | 4.06 | |||
| Information Ratio | 0.1077 | |||
| Jensen Alpha | 0.2052 | |||
| Total Risk Alpha | 0.074 | |||
| Sortino Ratio | 0.1413 | |||
| Treynor Ratio | 0.2656 | |||
| Maximum Drawdown | 9.78 | |||
| Value At Risk | (2.44) | |||
| Potential Upside | 4.5 | |||
| Downside Variance | 2.36 | |||
| Semi Variance | 1.62 | |||
| Expected Short fall | (1.74) | |||
| Skewness | 1.4 | |||
| Kurtosis | 3.81 |
| Risk Adjusted Performance | 0.1231 | |||
| Market Risk Adjusted Performance | 0.2756 | |||
| Mean Deviation | 1.44 | |||
| Semi Deviation | 1.27 | |||
| Downside Deviation | 1.54 | |||
| Coefficient Of Variation | 644.96 | |||
| Standard Deviation | 2.02 | |||
| Variance | 4.06 | |||
| Information Ratio | 0.1077 | |||
| Jensen Alpha | 0.2052 | |||
| Total Risk Alpha | 0.074 | |||
| Sortino Ratio | 0.1413 | |||
| Treynor Ratio | 0.2656 | |||
| Maximum Drawdown | 9.78 | |||
| Value At Risk | (2.44) | |||
| Potential Upside | 4.5 | |||
| Downside Variance | 2.36 | |||
| Semi Variance | 1.62 | |||
| Expected Short fall | (1.74) | |||
| Skewness | 1.4 | |||
| Kurtosis | 3.81 |
Consider Theravance Biopharma's intraday indicators
Theravance Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Theravance Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Theravance Biopharma Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Theravance Stock media impact
Far too much social signal, news, headlines, and media speculation about Theravance Biopharma that are available to investors today. That information is available publicly through Theravance media outlets and privately through word of mouth or via Theravance internal channels. However, regardless of the origin, that massive amount of Theravance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Theravance Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Theravance Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Theravance Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Theravance Biopharma alpha.
Theravance Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Theravance Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Theravance Biopharma Corporate Management
| Rhonda Farnum | Chief Affairs | Profile | |
| Andrew MBA | VP CFO | Profile | |
| Stacy Pryce | Senior Officer | Profile | |
| Stuart Knight | Senior Officer | Profile | |
| Gail Cohen | Vice Relations | Profile | |
| Rick MBA | Chairman CEO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Theravance Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.